Followers | 35 |
Posts | 6308 |
Boards Moderated | 0 |
Alias Born | 02/09/2015 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, February 23, 2015 9:23:18 PM
i see that Klebsiella is also mentioned in a Polymedix article, in addition to E Coli. This in and of itself is sensational. Daptomycin and Vancomycin would have NO gm - activity for example.
How is this relevant? let's take a common scenario- an IV drug user shows up in the Emergency Dept with an abscess. Usu they have a gm + source, but IV drug users can have unusual gm - too. One drug to get both? That is excellent, extraordinary.
You are free to doubt my motives, which are actually quite simple: at what point is CTIX ok to buy into? Even if Brilacidin is great, disappointing trial results with Kevetrin would have to lower share price. At the point when Kevetrin proves its worth in trials, or maybe even with good results in the next cohort or two, all those who have locked in shares will be big winners, and I will be struggling to get shares at a much higher price.
My other motive in watching this company is simple: these drugs would really benefit a lot of people. Since when does one small company have a potentially revolutionary antibiotic platform and a revolutionary chemo agent? From a clinical standpoint, a drug like Brilacidin would make the job of every physician easier(No I am not a pretend MD. I actually went to medical school and have practiced medicine for more than 20 years). And as I said prev, my sister in law has metastatic pancreatic CA, and Kevetrin might save some of those pts in the future.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM